Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer
William Butler(Duke University), Jiaoti Huang(Space Science Institute), Zachary C. Hartman(Duke University), Mu‐En Wang(Duke University), Robert D. Marek(Duke University), Yinglu Zhou(Dana-Farber Cancer Institute), J. Spencer Hauck(Duke University), Lingfan Xu(Duke University), Liang Cheng(Brown University), Ming Chen(Zhangzhou Municipal Hospital of Fujian Province), Hong Zhang(Duke University), Yiping He(Dalian University of Technology), Qing Yang(Guangzhou University of Chinese Medicine), Qing Cheng(National University of Defense Technology), Andrew J. Armstrong(Duke University)
Cited by 19
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k